Session I | 2026 Opening Session

“Lower for Longer”: Advancing Lipid Management in the Era of Evolving Evidence and 2026 Guideline Updates*

Co-hosted with the National Lipid Association and VindicoCME 

This fast‑paced program begins with an engaging, evidence‑based overview of newly updated guidelines and key clinical trial findings. From there, you’ll dive into real‑world case challenges that explore primary, moderate‑risk, and high‑risk patient scenarios. Through integrated audience polling, you’ll actively test your knowledge and decision‑making on topics such as risk assessment, LDL‑C and Lp(a) management, therapy selection, and treatment escalation.

Expert faculty will walk you through each case, break down the most relevant data, and translate emerging evidence into practical, actionable strategies you can apply immediately in your clinical practice.

By the end of this session, you’ll feel more confident applying current guidelines, evaluating new and emerging therapies, and supporting team‑based approaches to improving cardiovascular outcomes.

*Subject to change based on funding approval.

Session II | From Genetic Discovery to Clinical Action

• CRISPR-Based Gene Editing: Rewriting the Code for Lifetime Lipid Control and Cardiovascular Prevention   Ashish Sarraju, MD
• Genotype-Informed Prevention: The Economic Case for Cascade Screening in Familial Hypercholesterolemia   William Weintraub, MD
• Unlocking the Future of Cardiology: The Next Generation of Therapies Driven by Genetic Discovery  David Davidson, MD

Session IV | Severe Hypertriglyceridemia: A Comprehensive Exploration of Uncommon Causes and Emerging Insights

• Persistent Chylomicronemia, Looking Beyond FCS   Zahid Ahmad, MD, FNLA  
• GPIHBP1 Autoantibody Syndrome Explained   Katsuyuki Nakajima, PhD
• The Adipose Deficit: Recognizing Lipodystrophy as a Cause of Severe HTG   Vinaya Simha MBBS, MD

Session V | NLA/EAS Joint Session
Primary Prevention of ASCVD: a Joint Session from the European Atherosclerosis Society and the National Lipid Association

• Primary Prevention & Lp(a): The Updated Guidelines   Bø​rge Nordestgaard, MD, DMSc
• Using Imaging to Augment Primordial and Primary Prevention   Dinesh Kalra, MD, FNLA
• Combination Drug Therapy to Achieve Guideline Goals   Kausik Ray, MD, FMedSci
• How Do We Improve Implementation?   Kaye-Eileen Willard, MD, FNLA

Session VI | Rewriting the Rules for Primary Prevention: New Outcomes from Intensive LDL-C Reduction in High-Risk Patients

• The Original PCSK9 Inhibitor Trials: FOURIER, ODYSSEY Outcomes, FOURIER OLE   Bob Giugliano, MD
• What We've Learned about LDL-C and Outcomes   Nicholas Marston, MD
• VESALIUS-CV   Erin Bohula, MD, DPhil

Session X | Managing the Child's Trajectory: Intervening on Early Cardiometabolic Risk

• A Generation at Risk: Understanding and Mitigating Insulin Resistance in Youth   Jeanie Tryggestad, MD   
• Pre-Atherosclerotic Imaging in Pediatrics: Capturing Early Cardiovascular Risk   Justin Zachariah, MD
• Nurturing the Next Generation: A Family Affair of Health   Preneet Cheema Brar, MD, MS

Session XI | Deciphering Women's Risk: New Perspectives on Lipids, Pre-eclampsia, and Navigating HRT in Cardiometabolic Health

• When Pregnancy Predicts Heart Health: The Critical Role of Lipids in Pre-eclampsia  Tara Nowakthar, DO
• From Caution to Clarity: Re-evaluating the Risk-Benefit Profile of HRT after the FDA Policy Shift  Rachel Novik, DO
• Team-Based Care of Women with Cardiovascular Disease: From Pre-Conception Through Pregnancy and Postpartum  Brittany Katz, MD

Session XII | Inflammation: The GI, Metabolic and Renal Link

• Lipoprotein(a): The Genetic Inflammatory Fuel Driving Total Cardiovascular Risk   Michael Shapiro, DO
• The Role of Non-Invasive Imaging in Assessing MASLD-Related Inflammation and Fibrosis  Kathleen Wyne, MD, PhD
• Modulating the Gut Microbiome: A Novel Strategy for Attenuating Inflammation and Reducing Cardiorenal Risk   Michelle Routhenstein, MS, RD, CDCES, CDN